...
首页> 外文期刊>Journal of Medicinal Chemistry >Scaffold-Hopping and Structure-Based Discovery of Potent, Selective, And Brain Penetrant N-(1H-Pyrazol-3-yl)pyridin-2-amine Inhibitors of Dual Leucine Zipper Kinase (DLK, MAP3K12)
【24h】

Scaffold-Hopping and Structure-Based Discovery of Potent, Selective, And Brain Penetrant N-(1H-Pyrazol-3-yl)pyridin-2-amine Inhibitors of Dual Leucine Zipper Kinase (DLK, MAP3K12)

机译:双亮氨酸拉链激酶(DLK,MAP3K12)的有力,选择性和脑渗透性N-(1H-吡唑-3-基)吡啶-2-胺抑制剂的脚手架跳跃和基于结构的发现。

获取原文
获取原文并翻译 | 示例

摘要

Recent data suggest that inhibition of dual leucine zipper kinase (DLK, MAP3K12) has therapeutic potential for treatment of a number of indications ranging from acute neuronal injury to chronic neurodegenerative disease. Thus, high demand exists for selective small molecule DLK inhibitors with favorable drug-like properties and good CNS penetration. Herein we describe a shape-based scaffold hopping approach to convert pyrimidine 1 to a pyrazole core with improved physicochemical properties. We also present the first crystal structures of DLK. By utilizing a combination of property and structure-based design, we identified inhibitor 11, a potent, selective, and brain-penetrant inhibitor of DLK with activity in an in vivo nerve injury model.
机译:最新数据表明,抑制双亮氨酸拉链激酶(DLK,MAP3K12)具有治疗多种适应症的治疗潜力,从急性神经元损伤到慢性神经退行性疾病。因此,对具有良好的类药物性质和良好的CNS渗透性的选择性小分子DLK抑制剂存在很高的需求。在这里,我们描述了一种基于形状的支架跳跃方法,将嘧啶1转化为具有改善的理化性质的吡唑核。我们还介绍了DLK的第一个晶体结构。通过利用属性和基于结构的设计相结合,我们确定了抑制剂11,一种有效,选择性和脑渗透性的DLK抑制剂,在体内神经损伤模型中具有活性。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号